PIVKA-II:一种新型乙型肝炎相关肝癌诊断标记物研究进展  

PIVKA-II:a new biological marker in diagnosis of patients with hepatitis B-related hepatocellular carcinoma

作　　者：金盼盼(综述) 张岭漪(审校)[1] Jin Panpan;Zhang Lingyi(Department of Hepatology,Second Affiliated Hospital,Lanzhou University,Lanzhou 730030,Gansu Province,China)

机构地区：[1]兰州大学第二医院肝病科,兰州市730030

出　　处：《实用肝脏病杂志》2022年第4期605-608,共4页Journal of Practical Hepatology

摘　　要：目的病毒性肝炎,尤其是乙型肝炎病毒(HBV)感染是肝细胞癌(HCC)的主要致病因素。因缺乏早期症状,大部分HCC患者确诊时已为中晚期,因此预后不良。早诊断、早治疗是肝癌诊治的重要环节,现有的监测方法似乎不能显著提高肝癌的检出率。研究证实,维生素K缺失或拮抗剂-II诱导的蛋白质(PIVKA-II)有利于肝癌的早期诊断,本文对此进行了文献复习和综述。Objective Hepatocellar carcinoma(HCC)is still a heavy health burden in China.Hepatitis B and C infection is the main cause for it.Most patients with HCC are diagnosed at advanced stage with poor prognosis,owing to the lack of early symptoms.The present available monitoring approaches seem to unable to find liver cancer early.It is urgent to explore more sensitive markers to facilitate the early screening of liver cancer.The current research confirms that protein induced by vitamin K absence(PIVKA-II)is conducive to solving the problem.In this paper,we reviewed the progress on PIVKA-II as a new biological marker in this field.

关 键 词：肝细胞癌 乙型肝炎病毒 维生素K缺失或拮抗剂-II诱导的蛋白质 生物标志物 诊断 

分 类 号：R73[医药卫生—肿瘤]